Gentoo Media Inc. agrees EUR 50 million senior secured loan and secures full underwriting commitments for a planned EUR 50 million share issue to refinance its December 2026 bonds

REGULATORY NEWS•INSIDE INFORMATION•Nasdaq Stockholm: G2M

Gentoo Media Inc. - 1 October 2026, 08:00 CET

This information constitutes inside information that Gentoo Media Inc. (the "Company" or "Gentoo") is obliged to make public pursuant to the EU Market Abuse Regulation (Regulation (EU) No 596/2014, "MAR"). The information was submitted for publication at 08:00 CET on 1st October 2026.

BIRKIRKARA, Malta, Oct. 1, 2026 /PRNewswire/ --

- Gentoo Media PLC, a subsidiary of the Company, has agreed a EUR 50,000,000 senior secured term loan (the "Loan") with the Fundacja Zbigniewa Juroszka Fundacja Rodzinna ("ZJF"), a major shareholder of the Company (the "Lender").

- The Board of Directors of the Company (the "Board") plans to carry out a directed share issue of a new class of class of common stock targeting aggregate gross proceeds of EUR 50,000,000 (the "Share Issue"). The Share Issue is intended to be carried out during the fourth quarter of 2026, subject to further approvals, including the EGM approval of the increase in authorized share capital. Any decision to carry out the Share Issue and the final terms will be announced separately.

- The Company's largest shareholders, including MJ Foundation Fundacja Rodzinna ("MJF") and ZJF and Betplay Capital Fundacja Rodzinna (together, the "Backstop Providers") have signed commitments to fully underwrite any prospective Share Issue at a subscription price per share of SEK 6.1633, up to EUR 50,000,000.

- The Company has thereby secured commitments of in total EUR 100,000,000, an amount exceeding Gentoo Media P.L.C.'s outstanding ~EUR 91.5 million senior secured bonds 2023/2026 (the "Bonds").

- The combined net proceeds of the Loan and the Share Issue are intended to be applied to repay the Company's Bonds in full on the maturity date of 18 December 2026 and to further reduce the Company's debt facilities which currently stand at EUR 16,000,000 by ~EUR 8.5 million.

- The new capital structure returns control of the Group's cash flows to the Company: the Loan can be repaid at any time without penalty or premium, carries no equity component, and - once the Bonds are redeemed - gives the Board flexibility over time to consider returning capital to shareholders through dividends and share buybacks.

- To enable the Share Issue, the Board intends to convene an Extraordinary General Meeting ("EGM") to (i) increase the number of authorized shares of the Common Stock from 200,000,000 shares to 250,000,000 shares, and (ii) authorize an additional class of common stock, $0.001 par value per share, of the Company, to be designated "Class Z Common Stock," consisting of 100,000,000 shares, where the number of shares of Class Z Common Stock in issue will at no time exceed the number of authorized but unissued shares of Common Stock.

Background

Gentoo Media Inc. is the ultimate parent of the Gentoo group. The Company's existing Bonds were issued by subsidiary Gentoo Media P.L.C., with the Company and several subsidiaries as guarantor, and carry an aggregate outstanding nominal value of approximately EUR 91.5 million equivalent across a dual tranche of EUR and SEK, maturing on 18 December 2026.

The Board has, together with its advisers, evaluated refinancing alternatives ahead of the Bonds' maturity and has concluded that a combination of a new senior secured loan and a directed share issue, as described below, represents the most certain and appropriate solution for refinancing the Bonds in full and strengthening the Company's capital structure. The refinancing process has been led by an independent Refinancing Committee of the Board ("Committee"), with directors affiliated with the Lender taking no part in the Board's deliberations or resolutions on the financing. During 2026, the Company, assisted by an external financial adviser, conducted a broad market process in which more than 100 potential financing providers were approached and a number of firm financing offers were received. The Committee has also obtained an independent fairness opinion from Deloitte Malta, which concluded that the pricing and other key terms of the Loan are consistent with fair market conditions and compare favourably with the executable third-party alternatives.

The Loan

Gentoo Media PLC is the borrower under a EUR 50,000,000 senior secured Loan provided by the Lender. The Loan is senior secured, ranking at least pari passu with, and not junior to, other senior secured debt of the Group. Interest accrues at EURIBOR 3M plus 7.50% per annum, payable quarterly in cash, subject to a EURIBOR floor of 2.00%. The Loan matures on 18 December 2029 with mandatory amortisation of EUR 10,000,000 on each of the first and second anniversaries and the remaining EUR 30,000,000 due at final maturity. No arrangement or set-up fee is payable in respect of the Loan. The Company may prepay the Loan, in whole or in part, at any time without penalty or premium, and the Lender receives no equity kicker, warrants, conversion rights or other equity participation in the Company in connection with the Loan. This prepayment flexibility allows the Company to reduce debt from free cash flow at its own pace and at its own discretion.

As the Lender is a major shareholder of the Company, affiliated with Board members Mateusz Juroszek and Tomasz Juroszek, the Loan constitutes a related party transaction. The terms of the Loan were evaluated and negotiated by the independent Refinancing Committee of the Board, benchmarked against the firm offers obtained in the competitive market process described above, and are supported by an independent fairness opinion from Deloitte Malta, which concluded that the pricing and other key terms of the Loan are consistent with fair market conditions. The Board, with the board members affiliated with the Lender abstaining from the relevant deliberation and resolution related to the Loan, has concluded that the terms of the Loan are on market terms for a financing of this nature and type, having regard to the Company's financial position.

The Share Issue

The Board is seeking the necessary approvals to carry out a share issue after the Company has secured signed commitments from the Backstop Providers pursuant to which they undertake to subscribe for the total number of pro-rate shares allocated to them as well as any other shares not subscribed for by other eligible shareholders ("Backstop Shares"), ensuring that the Share Issue will be fully subscribed and deliver the target value of EUR 50,000,000. The subscription price agreed with the Backstop Providers, in respect of both their pro rata subscription rights ("Pro Rata Shares") and the Backstop Shares, is SEK 6.1633, which is equal to the volume-weighted average price of the Company's shares on Nasdaq Stockholm over the 12-month period ending on the trading day immediately preceding the date of this announcement, translated into EUR at the prevailing EUR/SEK reference exchange rate (the "Subscription Price").

The Board is planning a directed share issue of a new class of class of common stock (see further "EGM to approve Increase of Authorised Shares and Creation of New Class of Shares") targeting aggregate gross proceeds of EUR 50,000,000. The Company has secured signed commitments from the Backstop Providers (the "Underwriting Commitments") pursuant to which any new shares not subscribed for in the Share Issue by other eligible shareholders would be subscribed for by the Backstop Providers ("Backstop Shares"), to ensure the Share Issue is fully subscribed. The Underwriting Commitments are subject to customary conditions, and the subscription price for the Share Issue is SEK 6.1633, which is equal to the volume-weighted average price of the Company's shares on Nasdaq Stockholm over the 12-month period ending on 30 September 2026, (the "Subscription Price"), and constitutes a premium of approximately 58% to the closing price of the Company's shares on Nasdaq Stockholm on 30 September 2026.

The Backstop Providers are entities affiliated with the Juroszek family, which is a major shareholder of the Company; the underwriting arrangements accordingly also constitute a related party transaction, on the same basis as noted above in respect of the Loan.

The Share Issue is intended to be carried out during the fourth quarter of 2026, subject to further approvals, including the EGM approval of the increase in authorized share capital. Any decision to carry out the Share Issue and the final terms will be announced separately.

EGM to approve Increase of Authorised Shares and Creation of New Class of Shares

To enable the Share Issue, the Board intends to convene an EGM to (i) increase the number of authorised shares of the Common Stock, $0.001 par value per share, of the Company (the "Common Stock"), from 200,000,000 shares to 250,000,000 shares, and (ii) authorise an additional class of common stock, $0.001 par value per share, of the Company, to be designated "Class Z Common Stock," consisting of 100,000,000 shares. Before the Share Issue, the Company's authorised share capital is comprised of 200,000,000 shares of Common Stock, of which 134,707,974 are issued and listed. The number of shares of Class Z Common Stock in issue will at no time exceed the number of authorised but unissued shares of Common Stock. Upon the lapse of the 12-month lock-up period, holders of Class Z Common Stock may require the Company to convert their shares into Common Stock. Any such conversion, and the admission to trading of the resulting shares of Common Stock, will be subject to applicable securities-law requirements, including any prospectus required in connection with admission.

Invitation to media and analyst briefing for Ericsson Q3 2026 report

- Report to be released at approximately 7:00 AM CEST on October 15, 2026

- One live video webcast for analysts, investors and journalists at 9:00 AM CEST

STOCKHOLM, Oct. 1, 2026 /PRNewswire/ -- Ericsson's (NASDAQ: ERIC) financial report for the third quarter 2026 will be published at approximately 7:00 AM CEST on October 15, 2026. The company will issue a press release with the complete financial report attached, including tables, in PDF format. Following publication of the press release, the financial report will be available on Ericsson's website: https://www.ericsson.com/en/investors

President and CEO Per Narvinger and CFO Lars Sandström will comment on the report and take questions at a live video webcast at 9:00 AM CEST (8:00 AM BST London, 3:00 AM EDT New York).

Join the webcast or please go to www.ericsson.com/investors

To ask a question: Access dial-in information here

The webcast will be available on-demand after the event and can be viewed on our website.

NOTES TO EDITORS:

FOLLOW US:

MORE INFORMATION AT:

Ericsson Newsroom

[email protected]  (+46 10 719 69 92)

[email protected]  (+46 10 719 00 00)

ABOUT ERICSSON:

Ericsson's high-performing, programmable networks provide connectivity for billions of people every day. For 150 years, we've been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality. www.ericsson.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

SANTA MONICA, Calif., Sept. 30, 2026 /PRNewswire/ -- STARZ issued the following statement regarding the status of its negotiations with Verizon and the loss of all STARZ channels, STARZ On Demand and the STARZ app through Verizon Fios.

"Despite extensive efforts by STARZ to reach a renewal agreement and preserve uninterrupted access for Verizon Fios customers, Verizon has chosen to remove STARZ. Verizon has mischaracterized our position, shown an unwillingness to negotiate and has been unproductive in progressing towards a mutually beneficial outcome," said Alison Hoffman, President, STARZ Networks. "STARZ is one of the few remaining independent entertainment companies in a marketplace increasingly dominated by large media and telecommunications conglomerates. For decades, we have invested in storytelling that reflects a broad range of voices, experiences and perspectives, while championing creators and audiences that have historically been underrepresented in mainstream entertainment. Verizon's decision to drop STARZ deprives its customers of access to a unique slate of programming that cannot be found anywhere else and leaves viewers with fewer choices. We stand ready to reach a fair agreement that restores STARZ to Verizon customers as quickly as possible."

Since an agreement was not reached, customers have lost access to STARZ's programming, including the full "Power" Universe and the upcoming "Power: Origins," new hit drama "Fightland," every episode of the timeless romantic drama "Outlander" and its critically acclaimed prequel, "Outlander: Blood of my Blood," the upcoming season of the award-winning "P-Valley," the current season of the crime drama "S.W.A.T. Exiles," and the upcoming premiere of critically acclaimed drama, "Tip Toe," which are available exclusively on STARZ. Fans have also lost access to STARZ's extensive film library, including the global phenomenon Michael.

About STARZ

STARZ (NASDAQ: STRZ) is the leading premium entertainment destination for women and underrepresented audiences, and home to some of the most popular franchises and series on television. STARZ offers a robust programming mix for discerning adult audiences, including boundary-breaking originals and an expansive lineup of blockbuster movies, and is embodied by its brand positioning "We're All Adults Here." Complementary to any platform or service, STARZ is available across a wide range of digital OTT platforms and multichannel video distributors and is a bundling partner of choice. STARZ is powered by an industry-leading advanced technology, data analytics and digital infrastructure and the highly rated and first-of-its-kind STARZ app.

Press Inquiries - Contact:

Jennifer Minezaki

[email protected]    

Erin Moody

[email protected] 

Stephanie Lambert

[email protected]

SOURCE Starz Entertainment LLC

Share this article

Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

- Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab

- Results provide prospective clinical data on the use of eptinezumab in adults with migraine following inadequate response to one prior CGRP-targeting preventive therapy

- Eptinezumab was generally well tolerated with no new safety signals identified in this population

- Full results from the trial will be presented at upcoming scientific congresses

VALBY, Denmark, Oct. 1, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced headline results from the Phase IV interventional, open-label THRIVE trial (NCT06701526), evaluating eptinezumab in adults with migraine who had experienced an inadequate response to one prior calcitonin gene-related peptide (CGRP)-targeting preventive therapy.

THRIVE is the first interventional trial specifically designed to evaluate outcomes after treatment with eptinezumab in people with migraine who had experienced inadequate response to one previous CGRP-targeting preventive therapy. The trial addresses an important evidence gap, as there is currently limited clinical data to inform treatment sequencing for patients who received prior migraine preventive therapies.

In the THRIVE trial, participants received eptinezumab 100 mg at baseline, followed by dose escalation to 300 mg at week 12. At week 12, 44% of participants remaining in the trial reported being 'much improved' or 'very much improved' on the Patient Global Impression of Change (PGIC). At week 24, the trial's primary endpoint, 60% of participants remaining in the trial reported being 'much improved' or 'very much improved'.

"These results provide important prospective clinical trial data for people who continue to experience substantial migraine burden despite treatment with a prior CGRP-targeting preventive therapy," said Tarek Samad, Executive Vice President and Head of Research and Development at Lundbeck. "THRIVE was designed to help answer a clinically relevant question about what may come next for these patients, and these encouraging results add to the growing body of evidence supporting eptinezumab in migraine prevention. This is an important part of our continued commitment to helping more people achieve better control of this disabling neurological disease."

Reductions across monthly migraine days, monthly headache days, and acute medication use were also assessed, alongside measures of migraine-related burden. These findings will add further perspective to the overall improvement reported by participants on the PGIC. In addition, eptinezumab was well tolerated with no new safety signals identified in this patient population experiencing previous inadequate response to CGRP-targeting treatments.

Full results from THRIVE will be submitted for presentation at a future scientific congress and publication in a peer-reviewed journal.

About migraine

Migraine is a complex and disabling neurological disease characterized by recurrent attacks of severe headache typically accompanied by an array of symptoms, including nausea, vomiting, and sensitivity to light and sound. The disease can have a profound impact on daily functioning, work productivity, family, and social relationships and quality of life.

Migraine is one of the most prevalent neurological diseases worldwide and remains a leading cause of disability, particularly among people under the age of 50.1,2 As migraine frequency and severity increase, attacks may become harder to control, contributing to greater disease burden and, without appropriate preventive management, progression to chronic migraine.3

Despite recent advances in migraine-specific prevention, some patients continue to experience substantial migraine burden after an inadequate response to CGRP-targeting preventive therapies. Real-world studies of anti-CGRP monoclonal antibodies and preventive gepants have reported treatment discontinuation rates of approximately 40–45%, with inadequate effectiveness among the main reasons for discontinuation.4,5

About the THRIVE trial

The THRIVE trial was a 24-week, Phase IV, open-label, multicenter, interventional trial conducted in the United States evaluating the effectiveness and safety of eptinezumab in adults with migraine who had an inadequate response to one prior CGRP-targeting preventive therapy. The study enrolled 164 adults with at least eight monthly migraine days (MMD) who had previously received either a subcutaneous anti-CGRP monoclonal antibody or preventive gepant and had not received eptinezumab. All participants initiated eptinezumab 100 mg and subsequently escalated to 300 mg at Week 12 (147 participants received two infusions), and 84% (138/164) of participants completed the trial.

The primary endpoint was the proportion of participants reporting 'much improved' or 'very much improved' on the 7-point Patient Global Impression of Change (PGIC) scale (comprising 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', or 'very much worse') at Week 24. Secondary endpoints included reductions in MMDs, ≥50% MMD responder rate, patient-reported outcomes assessing changes in migraine burden (including MIDAS, number of good days, brain fog as well as goal attainment scaling [GAS], a novel endpoint in migraine trials). Safety and tolerability of eptinezumab were evaluated through assessment of adverse events and vital signs during the trial.

About Vyepti® (eptinezumab)

Eptinezumab is a humanized monoclonal antibody that binds to CGRP and was intentionally designed for intravenous administration. The efficacy and safety of eptinezumab were evaluated in two Phase III clinical trials, PROMISE-1 in episodic migraine6 and PROMISE-2 in chronic migraine.7 In both trials, eptinezumab met its primary endpoint of decrease in monthly migraine days (MMDs) over weeks 1-12.

The safety of eptinezumab was evaluated in more than 2,000 adult patients with migraine who received at least one dose of eptinezumab. The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity. Approximately 8% of patients on 300 mg, 6% of patients on 100 mg and 6% of patients on placebo in PROMISE-1 and PROMISE-2 experienced nasopharyngitis. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with eptinezumab discontinued treatment due to adverse reactions.

Since launch, the safety of eptinezumab has been evaluated in more than 5,000 adult patients with migraine who received at least one dose in the placebo-controlled clinical trials for the preventive treatment of migraine. Common adverse reactions were hypersensitivity and infusion-related reactions.

VYEPTI® (eptinezumab-jjmr) was approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing authorization by the European Commission (EC) for the prophylaxis of migraine in adults who have at least four migraine days per month. Today, eptinezumab is launched in more than 30 markets worldwide.

Contacts

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.

References

- Steiner TJ, et al. J Headache Pain. 2018;19(1):17

- Leonardi M, et al. J Headache Pain. 2005; 6(6):429– 440

- Lipton RB, et al. J Neurol. 2023;270(12);5692–5710

- Buse DC, et al. Neurol Ther. 2026;15(1):401–420

- Gago-Veiga AB, et al. J Headache Pain. 2026

- Ashina M, et al. Cephalalgia. 2020;40(3):241-254

- Lipton RB, et al. Neurology. 2020;94(13):e1365-e1377

CONTACT: 

H. Lundbeck A/S

Ottiliavej 9, 2500 Valby, Denmark

+45 3630 1311

[email protected] 

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

Share this article

Tres Agaves Tequila Launches in UK, Ireland and Continental Europe

Family-Owned Brand Brings Single-Source Organic Tequila to New Shores

ST. HELENA, Calif., Oct. 1, 2026 /PRNewswire/ -- Tres Agaves Tequila, the family-owned, 100% de Agave producer from Mexico's Tequila Valley, is launching in the UK and Ireland on October 1st, its first move into the European on-premise and independent retail trade. The rollout continues into Germany, Switzerland, the Nordics and Spain in the months that follow, with a formal European trade introduction at Bar Convent Berlin in mid-October.

Tres Agaves distills every drop from a single source in Amatitán, the birthplace of Tequila, built on nearly two decades of direct relationships with local growers. That single-estate sourcing, paired with USDA and Mexican organic certification and NOM-registered production, has made the brand a fixture behind U.S. bars. The UK and Ireland launch brings the same proposition to European bartenders and independent retailers for the first time.

"Tequila is one of the fastest-growing spirits categories in Europe, and bartenders want brands with real provenance," said Thomas Vogele, Vice President International Sales for Trinchero Family Wine & Spirits. "Tres Agaves gives the trade an organic, single-source Tequila from a genuinely family-owned producer, at a price accessible for the back bar rather than the top shelf."

The European Tequila market is set to reach a revenue of $2.49 billion by 2030, with a compound annual growth rate of 9.6% between 2025 and 2030. Tres Agaves is up +769% FYTD in the Trinchero Export Division. ¹ Stateside, Tres Agaves was recently named to Shanken's Impact 2026 "Hot Prospects" list, recognizing it among the fastest-growing spirits brands in the U.S.² Against this backdrop of growth, Tres Agaves is thrilled to offer its organic Tequila range to bartenders and consumers in the UK and Ireland and bring even more momentum to this vibrant category.

Launching in the UK & Ireland:

- Tres Agaves Blanco Tequila: unaged, bottled immediately after distillation; roasted agave, mint, citrus and pear.

- Tres Agaves Reposado Tequila: nine months in Tennessee whiskey and bourbon barrels; agave-forward with citrus, spice and baked tropical fruit. Wine Enthusiast Top 100 Spirit of the Year.

- Añejo and Extra Añejo: limited allocation for bars and retailers.

- Cocktail Mixers and Agave Nectar: USDA-certified organic Margarita and Bloody Mary mixes, plus cocktail-ready agave nectar.

Blanco and Reposado launch in a 700 ml pack size to meet European market requirements with suggested retail pricing ranging from £40-£45. Tres Agaves is exported by Trinchero Family Wine & Spirits.

¹ Source: Circana, Total MULO + with Conv + LIQ; L26wks ending 8/03/26

² Source: Shanken News Daily, "Exclusive: RTDs, Tequila Drive Lead Impact's 'Hot Prospects' List," September 14, 2026.

About Tres Agaves

Tres Agaves produces award-winning 100 percent de Agave Tequilas and USDA Organic cocktail mixers. Tres Agaves Tequilas are produced in the Tequila Valley using time-honored traditions. Its mixers are USDA certified organic, gluten-free and sweetened only with the finest blue weber agave nectar, making them the perfect choice for health and calorie conscious consumers. Tres Agaves cocktail-ready agave nectar, lime margarita, strawberry margarita, and Bloody Mary mixers were carefully formulated to help people make the most delicious cocktails possible by enhancing rather than overwhelming the flavors of high-quality Tequila. Visit www.tresagaves.com to learn more.

About Trinchero Family Wine & Spirits 

A family-owned company for more than 75 years, Trinchero Family Wine & Spirits comprises more than 50 award winning wine and spirits brands distributed globally. Founded in 1948 – when Italian immigrants Mario and Mary Trinchero moved their young family from New York City and purchased the Suter Home winery in St. Helena – Trinchero Family Wine & Spirits remains rooted in Napa Valley. From these humble beginnings Trinchero has grown to become one of the five largest US wineries through strategic partnerships and investments in technology and vineyards, all while maintaining a steadfast commitment to quality, value, sustainability and philanthropy. Learn more at www.tfewines.com.

Share this article

ICEYE and Nokia partner to launch secure and sovereign satellite communications for governments and defense customers

Sovereign, dual-use satellite communications systems owned and operated by the nations that use them.

HELSINKI, Oct. 1, 2026 /PRNewswire/ -- ICEYE, the European leader in sovereign intelligence from space, and Nokia, a global leader in connectivity infrastructure, today announced a partnership to develop secure, sovereign and high-performance broadband low Earth orbit (LEO) satellite communications systems for governments, supporting missions from defense and border security to emergency services and disaster response. Built on trusted European technology, the jointly developed satellite communications systems will give nations ownership and control of the satellites, ground segment and terminals. The first communications satellites are expected to be launched in 2028.

When terrestrial networks are disrupted or compromised, defense forces, first responders and civil authorities risk losing access to the information and command systems they depend on. Governments therefore need resilient communications infrastructure that remains available under the most demanding conditions, and that they can fully own and control.

The jointly developed sovereign systems will deliver targeted, high-throughput, low-latency connectivity over priority mission areas. Designed to complement military and commercial networks rather than replace them, it will add reach, resilience and capacity, helping governments and defense organizations maintain critical connections wherever operations take place.

The partnership brings together ICEYE's track record delivering sovereign satellite missions with Nokia's extensive experience in secure networking technologies and growing defense portfolio. Together, the companies will integrate satellites, ground infrastructure and ruggedized end-user terminals to extend ICEYE's sovereign intelligence from space business model to satellite communications.

Rafal Modrzewski, CEO and Co-founder of ICEYE, said: "Together with Nokia, we are building on our proven space intelligence expertise and delivering sovereign, high-performance satellite communications. Nations must be able to fully own and control their communications, without dependency on a foreign commercial operator's terms of service. We delivered Poland its own radar satellite system in under a year. Partnering with Nokia lets us move at a similar speed for satellite communications, on the timelines nations need."

Justin Hotard, President and CEO of Nokia, said: "Sovereign operations depend on the ability to sense, decide and act in real time. Physical AI makes that possible, but only with secure, resilient connectivity across land, sea, air and space. By bringing together Nokia's trusted networks with ICEYE's proven sovereign space capabilities, we will deliver a satellite communications capability—complementing existing terrestrial networks, and giving nations the situational awareness, connectivity, and control they need to operate with confidence in contested environments across all domains."

Modrzewski and Hotard will take the stage at the Helsinki Security Forum on October 2 for a session titled "How to Salvage Europe's Technological Sovereignty."

About ICEYE

ICEYE is the world leader in sovereign intelligence from space. We deliver persistent monitoring capabilities to detect and respond to changes in any location on Earth.

ICEYE owns the world's largest and most advanced SAR (synthetic aperture radar) satellite constellation. To our customers we provide intelligence with unmatched quality, latency and revisit times, in any weather, day or night. To governments who choose to operate their own constellation we provide this proven capability as a sovereign system.

ICEYE-built constellations serve customers in defense and intelligence, environmental monitoring, insurance and emergency management. We enable fast decisions that contribute to a safer future.

Natively European, founded in Finland. ICEYE operates globally with over 1,000 employees.

We're a growing international team of builders. iceye.com/joinus

About Nokia

Nokia is a global leader in connectivity infrastructure, enabling the AI supercycle. We build networks that connect intelligence and deliver a comprehensive connectivity solution across fixed, mobile, IP, optical, core, and data center networks. With security by design, AI-driven innovation, and AI-optimized architecture, Nokia delivers trusted infrastructure that enables AI to scale and advances connectivity to secure a brighter world.

Share this article

FORCYD expands into Switzerland and appoints Bob Dillen as Partner to lead Swiss practice

AMSTERDAM, Oct. 1, 2026 /PRNewswire/ -- FORCYD today announced its expansion into Switzerland with the opening of a new office in Zurich and the appointment of Bob Dillen as Partner leading the firm's Swiss practice.

Over recent years, FORCYD has built a reputation as Europe's premier eDiscovery, Investigations, and Cyber Forensics consultancies, growing from our Amsterdam origins to offices in Brussels, London, Frankfurt, Paris and Madrid. The relationships and standards we have developed reflect our core commitment to quality and client service.

The opening of our Zurich office enhances our ability to support clients locally in the DACH region while continuing to deliver cross-border expertise in complex legal and regulatory matters. The new office reflects the growing demand for specialist expertise in managing digital information across litigation, investigations, regulatory proceedings and other complex matters.

Bob Dillen brings more than two decades of international experience in forensic technology, eDiscovery and investigations, having advised organisations on arbitrational and dispute cases, regulatory matters and large-scale global investigations across multiple sectors.

Bas Sluijsmans, Partner and co-founder of FORCYD, comments:

"We are delighted to welcome Bob to FORCYD and to open our new office in Zurich. Bob is highly regarded in the market and brings decades of experience helping organisations navigate investigations, litigation and regulatory challenges. Just as importantly, we share the same commitment to quality, independence and client service. Bob will play a key role in our continued growth, and we look forward to building our Swiss practice and our global investigations offering together."

Bob Dillen adds:

"Having spent my career helping organisations navigate complex investigations, disputes and regulatory matters, I have seen first-hand the value of combining specialist expertise with a practical, hands-on approach. FORCYD shares that mindset, and I am delighted to join the firm and lead its Swiss practice."

About FORCYD

FORCYD offers high-end eDiscovery, cyber forensic and investigation advisory services and solutions. As an independent, globally operating consultancy with offices across Europe, FORCYD helps organisations and their advisers establish the facts and respond with confidence in matters involving misconduct, litigation, data breaches and other complex legal and regulatory challenges. We are called upon when the stakes are high, the matters complex, cross-border and time is of the essence, a trusted advisor to our clients and their legal counsels.

Share this article

Absa and Thunes Deepen Alliance to Launch World-Class Cross-Border Payments Across Africa

Strategic collaboration expands across African markets to unlock seamless FX, scalable liquidity, and multi-rail cross-border clearing for Absa clients.

JOHANNESBURG and SINGAPORE, Oct. 1, 2026 /PRNewswire/ -- Absa Group, one of Africa's largest diversified financial services providers, has selected Thunes, the Smart Superhighway to move money around the world, as a strategic Multicurrency Clearing (MCC) partner for the Group.

The new collaboration builds on the two companies' recent launch of Absa Global Pay in South Africa which demonstrated the value of combining Absa's strong banking franchise and Pan-African reach with Thunes' global payment connectivity and local-market capabilities. The expanded relationship will now support Absa's broader cross-border payments strategy across Africa and global markets.

Multicurrency Clearing forms a fundamental pillar of Absa's strategy to deliver greater speed, transparency, and choice in cross-border payments. By linking Absa's Pan-African banking footprint directly to Thunes' Direct Global Network, which spans over 140 countries, 90 currencies, and 220 payment methods, the collaboration enables seamless payouts beyond bank accounts to mobile wallets and card rails with 24/7 liquidity and enterprise-grade compliance.

Richard Southey, Managing Executive: Payments as a Service, Absa CIB, said: "Deepening our strategic collaboration with Thunes is a natural evolution of our commitment to delivering intuitive, world-class financial services. Following the success of our Global Pay solution launched with Thunes in South Africa, expanding this collaboration allows Absa to leverage Thunes' expansive and trusted Network across the continent to extend our cross-border solution, giving our clients unprecedented currency choice, speed, and cost efficiency."

Daniel Parreira, Senior Vice President, Africa at Thunes, said: "Our initial work with Absa demonstrated the tremendous impact of combining deep local banking relationships with interoperable global payment reach. By extending our collaboration and taking on a strategic Multicurrency Clearing role supporting Absa Group, we are providing the digital infrastructure and liquidity needed to connect African businesses and consumers to global payment ecosystems seamlessly."

To celebrate this milestone, executive leaders from both organisations gathered for an official signing ceremony at SIBOS 2026 in Miami.

About Thunes

For more information, visit: https://www.thunes.com/

About Absa Group Limited

Absa Group Limited ('Absa Group') is listed on the Johannesburg Stock Exchange and is one of Africa's largest diversified financial services groups.

Absa Group offers an integrated set of products and services across personal and business banking, corporate and investment banking, wealth and investment management and insurance.

Absa Group owns majority stakes in banks in Botswana, Ghana, Kenya, Mauritius, Mozambique, Seychelles, South Africa, Tanzania (Absa Bank Tanzania and National Bank of Commerce), Uganda and Zambia and has insurance operations in Kenya and South Africa. Absa also has offices in the People's Republic of China, Namibia, Nigeria and the United States, as well as securities entities in the United Kingdom and the United States, along with technology support colleagues in the Czech Republic.

For further information about Absa Group Limited, visit www.absa.africa.

SOURCE Thunes

Share this article

Three Companies Control 80% of the Prescription Market. AlignRx Built a Public Benefit LLC to Push Back, and Tells the Story on "All Access with Andy Garcia"

LOS ANGELES, Oct. 1, 2026 /PRNewswire/ -- A forthcoming feature on the public television series All Access with Andy Garcia goes behind the counter at community pharmacies, exploring the vital role pharmacists play as some of the most accessible and trusted healthcare providers—and the growing fight for fair reimbursement needed to keep these neighborhood cornerstones open.

The feature examines not only the importance of local pharmacies to an individual's health, but also what happens behind the counter after the conversation between pharmacist and patient ends. That includes navigating complex systems of insurance contracting and claims reimbursement, particularly when a pharmacy is reimbursed less than the cost of the medication it dispenses. Against this backdrop, the feature highlights the role AlignRx plays in helping community pharmacies navigate these challenges and advocate for a more transparent and sustainable reimbursement environment.

AlignRx is the nation's largest independently owned Pharmacy Services Administrative Organization (PSAO), working with community pharmacies in all 50 states and Puerto Rico. Founded in 2021 as a Public Benefit LLC—the only PSAO organized under this structure—AlignRx works to protect the future of community pharmacy by advocating for increased transparency, fair competition, pharmacy choice and patient access.

Last year, three pharmacy benefit managers—CVS Caremark, Optum Rx, and Express Scripts—processed roughly 80% of U.S. prescription claims, and this market consolidation has led to a vertically integrated system where patients can face higher out-of-pocket costs and lack of choice, potentially severing existing relationships with their trusted local pharmacists. Melanie Maxwell, president of AlignRx, describes the imbalance between community pharmacies and larger industry players as a modern-day "David and Goliath" story.

For Maxwell, the fight is personal. During the final months of her parents' lives, Maxwell found herself spending more time at a pharmacy counter than in a physician's office, asking questions someone needed to answer that day. That experience turned into a 35-year career in pharmacy and is the thread running through the forthcoming short-form documentary distributed to Public Television stations across the country.

The pressure on community pharmacies is at an all-time high and is leading to critical gaps in care for some of the nation's most vulnerable populations. Research shows pharmacies serving communities with higher concentrations of Medicaid and Medicare patients have closed at greater rates, contributing to the spread of pharmacy deserts across rural counties and urban neighborhoods alike.

"The relationship across the patient, the physician, and the pharmacist is like a three-legged stool," said Maxwell. "If you remove one of those legs, the patient—the one sitting on the stool—gets hurt. When we weaken the community pharmacy, we're not just affecting a business, we're affecting the patient who depends on that pharmacist for access, answers and care."

About "All Access with Andy Garcia": All Access with Andy Garcia is an award-winning short-form documentary series produced by a veteran team of producers and distributed to Public Television stations nationwide. The program examines the topics, industries and community institutions shaping daily life, with educational features intended for a general audience. More information is available at allaccessptv.com

About AlignRx: AlignRx is the nation's largest independently owned PSAO, representing nearly 5,300 community pharmacies across the USA and Puerto Rico. The company empowers pharmacy businesses with comprehensive, data-driven solutions built to streamline operations. At AlignRx, every pharmacy selects their own wholesaler or buying group. Its mission is to ensure the vitality and growth of community pharmacy. Learn more at alignrx.org

SOURCE All Access

Share this article

- 2026 WRC season finale to take place from October 1 to 4 around Alghero, Sardinia, Italy

- Dynapro R213 all-terrain rally tires engineered for rugged terrain, including rocky sections

- Hankook demonstrates global motorsport expertise through exclusive WRC tire supply and data accumulated across approximately 70 competitions worldwide

ALGHERO, Italy, Oct. 1, 2026 /PRNewswire/ -- A leading global tire company Hankook Tire & Technology (Hankook), the exclusive tire supplier to the FIA World Rally Championship (WRC), is set for the final round of the season, Rally Italia Sardegna, taking place from October 1 to 4 around Alghero on the island of Sardinia, Italy.

Now in its 23rd edition, Rally Italia Sardegna is a historic gravel event. With Rally Saudi Arabia, originally scheduled as the final round, removed from the WRC calendar, the Italian contest will close out the 2026 season. As the Drivers' Championship will be decided here, strategies for tackling demanding roads and unpredictable October weather, along with tire performance, are expected to play a crucial role.

The rally comprises 17 Special Stages (SS) covering approximately 307.02 competitive kilometers on unpaved roads. Narrow, winding sections bordered by trees and undergrowth, together with blind crests, limit visibility and leave little room for error.

The route also features Micky's Jump, one of the event's best-known sections, alongside deep ruts formed by repeated runs and rough rocky stretches. These elements place high demands on tire durability and vehicle stability, making consistent control a key factor throughout the rally.

Hankook will supply the Dynapro R213, its all-terrain rally tire, in Hard and Soft compounds to support teams through the season-ending event. The tire is designed to absorb impacts from gravel while providing stable grip and precise handling and robust durability across demanding stages.

At Round 12, Rally Chile Biobío, Toyota GAZOO Racing World Rally Team's Oliver Solberg claimed his second victory of the year following his win at Rallye Monte-Carlo. The result secured Toyota the 2026 Manufacturers' Championship, marking the team's sixth consecutive title since 2021 and its 10th overall. With the manufacturers' crown decided, the Drivers' Championship will be settled at Rally Italia Sardegna.

Hankook demonstrates its world-class motorsport technology as the exclusive rally tire supplier across all WRC classes. By actively leveraging extensive driving data accumulated across approximately 70 motorsport competitions worldwide, including the WRC, in its research and development (R&D), the company drives innovation in high-performance tire technology while strengthening its competitiveness as a global top-tier brand.

Share this article